(TX_TB) Proportion of ART patients screened for TB in the semiannual reporting period who start TB treatment.
This indicator documents the TB screening of ART patients as well as the proportion who were diagnosed and started on TB therapy. The disaggregates demonstrate the cascade from screening to testing and can be used to identify gaps and challenges in TB diagnostic activities among ART patients.
Number of ART patients who were started on TB treatment during the semiannual reporting period.
Number of ART patients who were screened for TB at least once during the semiannual reporting period.
How to calculate annual total:
It is preferred to analyze this indicator as a snapshot indicator (i.e., the result reported at Q4) when viewing this data in conjunction with TB_PREV data; in other words, when one is analyzing the PEFPAR TB/HIV Screening Cascade. The TX_TB Denominator should not be summed over the semiannual time periods since it is a snapshot indicator that captures a clinical event (screening), not unique patients. However, note that the TX_TB Numerator, if analyzed on its own, could be summed across semiannual time periods to conclude the number of ART patients who were started on TB treatment during the fiscal year.
The denominator can be generated by counting the number of ART patients who were screened for TB symptoms at least once during the reporting period. This includes newly enrolling ART patients as well as those previously started on ART.
The numerator can be generated by counting the number of screened ART patients who were diagnosed with TB and started on anti-TB therapy during the reporting period. These data should be captured in ART registers as well as additional data collection sources (e.g., facility-based TB screening registers or forms, TB specimen registers, TB microscopy result registers, GeneXpert data collection systems) that may contain relevant information (e.g., TB screening results, TB specimen testing results). Programs should modify the register as needed to easily capture this information.
Documentation of symptom screening is generally collected in patient charts but may also be collected in another aggregate partner-generated data source.
Screening for TB and/or initiation of anti-TB therapy might not happen at the same time that ART is started. For PLHIV new to HIV care, those who are diagnosed with TB are usually started on anti-TB therapy before they initiate ART (e.g., 2-8 weeks as per current recommendations). Regardless of when they occur relative to ART initiation, TB screening and initiation of TB therapy should be included for all patients who were currently on ART or who started ART at any time during the reporting period.
Further information on how to use and collect these data is provided by WHO in the following guidelines: “Latent Tuberculosis Infection: Updated and Consolidated Guidelines for Programmatic Management.”
How to review for data quality:
The numerator can be generated by counting the number of screened ART patients who were diagnosed with TB and started on anti-TB therapy during the reporting period.
The denominator can be generated by counting the number of ART patients who were screened for TB symptoms at least once during the reporting period.
Indicator changes (MER 2.0 v2.2 to v2.3):